jrnl3032

Publication Venue For

  • Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial.  68:1981-1989. 2019
  • Plasma 25-Hydroxyvitamin D and the Longitudinal Risk of Sepsis in the REGARDS Cohort.  68:1926-1931. 2019
  • Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings.  68:1136-1143. 2019
  • Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.  68:1144-1151. 2019
  • A 9-Point Risk Assessment for Patients Who Inject Drugs and Require Intravenous Antibiotics: Focusing Inpatient Resources on Patients at Greatest Risk of Ongoing Drug Use.  68:1041-1043. 2019
  • Ceftriaxone-resistant Salmonella Typhi Outbreak in Hyderabad City of Sindh, Pakistan: High Time for the Introduction of Typhoid Conjugate Vaccine.  68:S16-S21. 2019
  • Safety and efficacy of a novel vaginal anti-infective, TOL-463, in the treatment of bacterial vaginosis and vulvovaginal candidiasis: A randomized, single-blind, phase 2, controlled trial.  68:803-809. 2019
  • Depressive Symptoms and Engagement in Human Immunodeficiency Virus Care Following Antiretroviral Therapy Initiation.  68:475-481. 2019
  • Impact of infectious disease consultation on clinical management and mortality in patients with candidemia.  68:1585-1587. 2019
  • Molecular-based testing for sexually transmitted infections using samples previously collected for vaginitis diagnosis.  68:375-381. 2019
  • The North-South divide: Substance use risk, care engagement, and viral suppression among hospitalized human immunodeficiency virus-infected patients in 11 US cities.  68:146-149. 2019
  • Cumulative burden of depression and all-cause mortality in women living with human immunodeficiency virus.  67:1575-1581. 2018
  • A Brief History of Evolving Diagnostics and Therapy for Gonorrhea: Lessons Learned.  67:1294-1299. 2018
  • Application of a Multistate Model to Evaluate Visit Burden and Patient Stability to Improve Sustainability of Human Immunodeficiency Virus Treatment in Zambia.  67:1269-1277. 2018
  • No Impact of Hepatitis B Virus Infection on Early Mortality among Human Immunodeficiency Virus-Infected Patients in Southern Africa.  67:1310-1311. 2018
  • Large Outbreak of Hepatitis C Virus Associated with Drug Diversion by a Healthcare Technician.  67:845-853. 2018
  • Cytomegalovirus Shedding in Seropositive Pregnant Women from a High-Seroprevalence Population: The Brazilian Cytomegalovirus Hearing and Maternal Secondary Infection Study.  67:743-750. 2018
  • Why does trichomonas vaginalis continue to be a "neglected" sexually transmitted infection?.  67:218-220. 2018
  • Association of Neighborhood Socioeconomic Status with Risk of Infection and Sepsis.  66:1940-1947. 2018
  • ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants with HIV-1 RNA <500000 Copies/mL.  66:1689-1697. 2018
  • Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel.  66:1678-1686. 2018
  • Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.  66:1794-1797. 2018
  • Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials.  66:1492-1500. 2018
  • Multimorbidity among Persons Living with Human Immunodeficiency Virus in the United States.  66:1230-1238. 2018
  • Management of an Outbreak of Exophiala dermatitidis Bloodstream Infections at an Outpatient Oncology Clinic.  66:959-962. 2018
  • High prevalence of multidrug-resistant mycoplasma genitalium in human immunodeficiency virus-infected men who have sex with men in Alabama.  66:796-798. 2018
  • Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis among Adolescent and Young Men Who Have Sex with Men in the United States.  66:213-219. 2018
  • Improved Retention with 6-Month Clinic Return Intervals for Stable Human Immunodeficiency Virus-Infected Patients in Zambia.  66:237-243. 2018
  • Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults with Human Immunodeficiency Virus Infection Being Treated with Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.  66:220-228. 2018
  • A silent epidemic: The prevalence, incidence and persistence of mycoplasma genitalium among young, asymptomatic high-risk women in the United States.  67:73-79. 2018
  • Outbreak of Foodborne Botulism in an Immigrant Community: Overcoming Delayed Disease Recognition, Ambiguous Epidemiologic Links, and Cultural Barriers to Identify the Cause.  66:S82-S84. 2017
  • The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus Infection.  65:2042-2049. 2017
  • Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women.  65:1695-1702. 2017
  • Mycoplasma hominis Infections Transmitted Through Amniotic Tissue Product.  65:1152-1158. 2017
  • CD4:CD8 Ratio and CD8 Count as prognostic markers for mortality in human immunodeficiency virus-infected patients on antiretroviral therapy: The antiretroviral therapy cohort collaboration (ART-CC).  65:959-966. 2017
  • Continued evolution of gonococcal antimicrobial resistance.  65:924-926. 2017
  • Cancer-Attributable Mortality among People with Treated Human Immunodeficiency Virus Infection in North America.  65:636-643. 2017
  • Risk of Acute Coronary Heart Disease after Sepsis Hospitalization in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort.  65:29-36. 2017
  • Antiretroviral therapy initiation and changes in self-reported depression.  64:1791-1794. 2017
  • Impact of Antiretroviral Therapy on Liver Fibrosis among Human Immunodeficiency Virus-Infected Adults with and Without HBV Coinfection in Zambia.  64:1343-1349. 2017
  • Association of Diabetes and Insulin Therapy With Risk of Hospitalization for Infection and 28-Day Mortality Risk..  64:435-442. 2017
  • Association of diabetes and insulin therapy with risk of hospitalization for infection and 28-day mortality risk.  64:435-442. 2017
  • Continuum of care for hepatitis C virus among patients diagnosed in the emergency department setting.  64:1540-1546. 2017
  • Decline in bone mass with tenofovir disoproxil fumarate/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis.  64:317-325. 2017
  • Incident AIDS or death after initiation of human immunodeficiency virus treatment regimens including raltegravir or efavirenz among adults in the United States.  64:1591-1596. 2017
  • Angiostrongylus cantonensis Infection: A Cause of Fever of Unknown Origin in Pediatric Patients.  63:1475-1478. 2016
  • Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe, and Asia.  63:1245-1253. 2016
  • Durable Viral Suppression and Transmission Risk Potential among Persons with Diagnosed HIV Infection: United States, 2012-2013.  63:976-983. 2016
  • The Veterans Aging Cohort Study (VACS) Index and Neurocognitive Change: A Longitudinal Study.  63:694-702. 2016
  • Successful re-treatment of hepatitis C virus in patients coinfected with HIV Who relapsed after 12 weeks of ledipasvir/sofosbuvir.  63:528-531. 2016
  • Editorial Commentary: Affordable Care Act, Medicaid Expansion ... or Not: Ryan White Care Act Remains Essential for Access and Equity.  63:404-406. 2016
  • Reply to Simon and to Eljaaly and Nix..  63:287-288. 2016
  • Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy among HIV-infected Patients Followed for up to 15 Years after Start of Treatment: Collaborative Cohort Study.  62:1571-1577. 2016
  • Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor.  62:1329-1335. 2016
  • Emergency Department Screening for Hepatitis C Virus: Geographic Reach and Spatial Clustering in Central Alabama.  62:613-616. 2016
  • Home Screening for Bacterial Vaginosis to Prevent Sexually Transmitted Diseases.  62:531-536. 2016
  • Inpatient mortality among solid organ transplant recipients hospitalized for sepsis and severe sepsis.  63:186-194. 2016
  • A Review of Evidence-Based Care of Symptomatic Trichomoniasis and Asymptomatic Trichomonas vaginalis Infections.  61:S837-S848. 2015
  • Diagnosis and Management of Uncomplicated Chlamydia trachomatis Infections in Adolescents and Adults: Summary of Evidence Reviewed for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.  61:S774-S784. 2015
  • Immunization costs and programmatic barriers at an urban HIV clinic.  61:1726-1731. 2015
  • Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.  61:1573-1581. 2015
  • Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.  62:e1-e50. 2015
  • Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.  62:409-417. 2015
  • Host-directed therapies for tackling multi-drug resistant tuberculosis: Learning from the pasteur-bechamp debates.  61:1432-1438. 2015
  • Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison with Antigen Testing.  61:1293-1303. 2015
  • Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections.  61:601-606. 2015
  • Reply to Bauer and Goff.  61:487-488. 2015
  • Dynamic visual display of treatment response in HIV-infected adults.  61:e1-e4. 2015
  • Predicting risk of endocarditis using a clinical tool (PREDICT): Scoring system to guide use of echocardiography in the management of Staphylococcus aureus bacteremia.  61:18-28. 2015
  • Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: Cross-sectional analysis of a multisite retrospective cohort study.  60:1145-1152. 2015
  • A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea.  61:1043-1048. 2015
  • Age at Entry into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality among HIV-Seropositive Adults in the United States.  61:1189-1195. 2015
  • Application of the 2008 definitions for invasive fungal diseases to the trial comparing voriconazole versus amphotericin B for therapy of invasive aspergillosis: A Collaborative Study of the Mycoses Study Group (MSG 05) and the European Organization for Research and Treatment of Cancer Infectious Diseases Group.  60:713-720. 2015
  • Editorial Commentary: Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROL.  61:169-170. 2015
  • Editorial commentary: Women who have sex with women: A unique population for studying the pathogenesis of bacterial vaginosis.  60:1054-1056. 2015
  • End-stage renal disease among HIV-infected adults in North America.  60:941-949. 2015
  • Eosinophil-associated processes underlie differences in clinical presentation of loiasis between temporary residents and those indigenous to loa-endemic areas.  60:55-63. 2015
  • Extended-release niacin versus fenofibrate in HIV-infected participants with low high-density lipoprotein cholesterol: Effects on endothelial function, lipoproteins, and inflammation.  61:840-849. 2015
  • Fixing a hole in the HIV safety net.  60:126-127. 2015
  • Herpes simplex encephalitis: Lack of clinical benefit of long-term valacyclovir therapy.  61:683-691. 2015
  • Impact of early valve surgery on outcome of staphylococcus aureus prosthetic valve infective endocarditis: Analysis in the international collaboration of endocarditis-prospective cohort study.  60:741-749. 2015
  • Less Bone Loss with Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.  61:1179-1188. 2015
  • Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.  60:703-712. 2015
  • T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: A clinical trial.  60:892-899. 2015
  • Ten-year survival by race/ethnicity and sex among treated, HIV-infected adults in the United States.  60:1700-1707. 2015
  • Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics.  60:1377-1383. 2015
  • Waning efficacy of the herpes zoster vaccine.  60:910-911. 2015
  • The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.  59:1083-1091. 2014
  • Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic.  59:834-841. 2014
  • National estimates of healthcare utilization by individuals with hepatitis C virus infection in the United States.  59:755-764. 2014
  • Enhanced personal contact with HIV patients improves retention in primary care: A randomized trial in 6 US HIV clinics.  59:725-734. 2014
  • Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients.  59:287-297. 2014
  • Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort.  59:279-286. 2014
  • Reply to rapose.  59:316-317. 2014
  • Reversible blindness in cryptococcal meningitis with normal intracranial pressure: Case report and review of the literature.  59:310-313. 2014
  • Addressing the achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation.  59. 2014
  • HIV viremia and incidence of non-Hodgkin lymphoma in patients successfully treated with antiretroviral therapy.  58:1599-1606. 2014
  • Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.  58:1467-1472. 2014
  • Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.  58:1473-1480. 2014
  • Antibiotic hypersensitivity reactions and approaches to desensitization.  58:1140-1148. 2014
  • Disparities in the quality of HIV care when using US department of health and human services indicators.  58:1185-1189. 2014
  • Erratum: Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The Influenza Resistance Information Study (IRIS) (Clinical Infectious Diseases (2013) 56 (1197-205)).  58:1203. 2014
  • Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.  58:413-422. 2014
  • Church attendance in men who have sex with men diagnosed with HIV is associated with later presentation for HIV care.  58:295-299. 2014
  • An expanded role for therapeutic lumbar punctures in newly diagnosed aids-associated cryptococcal meningitis?.  59:1615-1617. 2014
  • Beyond core indicators of retention in HIV care: Missed clinic visits are independently associated with all-cause mortality.  59:1471-1479. 2014
  • Chronic hepatitis B virus coinfection is associated with renal impairment among zambian HIV-infected adults.  59:1757-1760. 2014
  • Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care.  59:1686-1693. 2014
  • Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.  58:1312-1321. 2014
  • Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials.  58:1297-1307. 2014
  • MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.  58:1219-1226. 2014
  • Histoplasmosis after solid organ transplant.  57:1542-1549. 2013
  • Case definitions, diagnostic algorithms, and priorities in encephalitis: Consensus statement of the international encephalitis consortium.  57:1114-1128. 2013
  • Reply to Yang et al.  57:1212-1213. 2013
  • The state of engagement in HIV care in the United States: From cascade to continuum to control.  57:1164-1171. 2013
  • A systematic review and meta-regression of temporal trends in adult CD4+ cell count at presentation to HIV care, 1992-2011.  57:1027-1037. 2013
  • Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.  57:735-744. 2013
  • Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy.  57:756-764. 2013
  • Clinical reasoning for the infectious disease specialist: A primer to recognize cognitive biases.  57:573-578. 2013
  • Long-term outcomes of a cell phone-delivered intervention for smokers living with HIV/AIDS.  57:608-615. 2013
  • Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe, and the United States.  56:1800-1809. 2013
  • Syphilis treatment response among HIV-discordant couples in Zambia and Rwanda.  56:1829-1837. 2013
  • Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.  56:1471-1479. 2013
  • Reply to oude lashof and vogelaers.  56:1515-1516. 2013
  • Global assessment of resistance to neuraminidase inhibitors, 2008-2011: The influenza resistance information study (IRIS).  56:1197-1205. 2013
  • Trends and disparities in antiretroviral therapy initiation and Virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009.  56:1174-1182. 2013
  • Erratum: Changing epidemiology of herpes simplex virus infections (Clinical Infectious Diseases (2013) 56 (352-353)).  56:1066. 2013
  • Editorial Commentary: Sexual networks, sex hormones, and recurrent bacterial vaginosis: Not such strange bedfellows.  56:787-879. 2013
  • Editorial commentary: Changing Epidemiology of Herpes Simplex Virus Infections.  56:352-353. 2013
  • Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women.  56:344-351. 2013
  • Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin.  56:420-422. 2013
  • Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke.  56:209-217. 2013
  • Congenital cytomegalovirus infection: clinical outcome..  57 Suppl 4. 2013
  • Editorial commentary: A syphilis wish list: Better data, better tests.  55:1623-1624. 2012
  • Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.  55:1550-1557. 2012
  • Editorial commentary: Viva no différence!.  55:1252-1254. 2012
  • Novel pneumococcal serotypes 6C and 6D: Anomaly or harbinger.  55:1379-1386. 2012
  • A low-effort, clinic-wide intervention improves attendance for HIV primary care.  55:1124-1134. 2012
  • Clinical scoring for risk of resistant organisms in pneumonia: Right idea, wrong interpretation.  55:749-750. 2012
  • Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease.  55. 2012
  • Reply to Anaissie and Nucci and to Cisneros et al.  55:894-895. 2012
  • Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent trials network study 021B.  55:461-468. 2012
  • Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital chlamydia trachomatis infection: A randomized, double-blind, double-dummy, active-controlled, multicenter trial.  55:82-88. 2012
  • Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: A patient-level quantitative review of randomized trials.  54:1110-1122. 2012
  • Reply to Keynan.  54:1037-1038. 2012
  • Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: A randomized, placebo-controlled trial.  54:1013-1025. 2012
  • Differential occurrence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of pathogen microevolution.  54:794-799. 2012
  • Patient reported outcomes in routine care: Advancing data capture for HIV cohort research.  54:141-147. 2012
  • Diagnosis and management of uncomplicated chlamydia trachomatis infections in adolescents and adults: Summary of evidence reviewed for the 2010 centers for disease control and prevention sexually transmitted diseases treatment guidelines.  53. 2011
  • Interventions to prevent sexually transmitted infections, including HIV infection.  53. 2011
  • Sexually transmitted infections among women who have sex with women.  53. 2011
  • Trichomonas vaginalis genital infections: Progress and challenges.  53. 2011
  • Essential components of effective HIV care: A policy paper of the HIV medicine association of the infectious diseases society of america and the ryan white medical providers coalition.  53:1043-1050. 2011
  • HIV now firmly established in the middle ages.  53:1140-1142. 2011
  • Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis.  53:1092-1099. 2011
  • The spectrum of engagement in HIV care: Do more than 19%of HIV-infected persons in the US have undetectable viral load?.  53:1168-1169. 2011
  • Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.  53:927-935. 2011
  • Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.  53:807-816. 2011
  • Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort.  53:826-835. 2011
  • Ocular manifestations of candidemia.  53:262-268. 2011
  • Slowly progressive annular skin lesions in an elderly patient..  52. 2011
  • Erratum: High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy (Clinical Infectious Diseases (2011) 52 (378-386)).  52:1200. 2011
  • Transmission of Cryptococcus neoformans by organ transplantation.  52. 2011
  • Comparative effectiveness and toxicity of statins among HIV-infected patients.  52:387-395. 2011
  • High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy.  52:378-386. 2011
  • Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the us general population.  52:396-405. 2011
  • NK cells, innate immunity and hepatitis C infection after liver transplantation.  52:369-377. 2011
  • Health care system and policy factors influencing engagement in HIV medical care: Piecing together the fragments of a fractured health care delivery system.  52. 2011
  • Re-evaluating the treatment of nongonococcal urethritis: Emphasizing emerging pathogens - A randomized clinical trial.  52:163-170. 2011
  • Reply to Johnson and Stricker.  51:1109-1110. 2010
  • Bone disease in HIV infection: A practical review and recommendations for HIV care providers.  51:937-946. 2010
  • Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.  51:718-724. 2010
  • How do HIV elite controllers do what they do?.  51:239-241. 2010
  • Reply to Hoenigl et al.  51:254-255. 2010
  • Factors associated with mortality in transplant patients with invasive aspergillosis.  50:1559-1567. 2010
  • Late presentation for human immunodeficiency virus care in the United States and Canada.  50:1512-1520. 2010
  • Causes of death in HIV-1-Infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies.  50:1387-1396. 2010
  • Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (Transnet).  50:1101-1111. 2010
  • Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant- associated infection surveillance network (TRANSNET) database.  50:1091-1100. 2010
  • Routine, self-administered, touch-screen, computer-based suicidal ideation assessment linked to automated response team notification in an HIV primary care setting.  50:1165-1173. 2010
  • Erratum: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. (Clinical Infectious Diseases (2009) 49:(1-45)).  50:1079. 2010
  • Blastomycosis of the central nervous system: A multicenter review of diagnosis and treatment in the modern era.  50:797-804. 2010
  • Sex and gender differences in travel-associated disease.  50:826-832. 2010
  • Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.  50:912-919. 2010
  • Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care.  50:574-584. 2010
  • Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America.  50:291-322. 2010
  • Cryptococcosis in the developing world: An elephant in the parlor.  50:345-346. 2010
  • Erratum: Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. (Clin Infect Dis (2009) 49 (1-45)).  50:457. 2010
  • Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month through 11 years of age.  50:221-228. 2010
  • High serum cholesterol levels are associated with herpes zoster infection after heart transplantation.  50:121-122. 2010
  • Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent trials network study 021.  50:106-114. 2010
  • Reply to Collins et al and Manian.  49:1771-1772. 2009
  • Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.  49:1582-1590. 2009
  • Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: A prospective multicenter study.  49:931-934. 2009
  • Birth prevalence and natural history of congenital cytomegalovirus infection in a highly seroimmune population.  49:522-528. 2009
  • Reply to kontoyiannis.  49:639-640. 2009
  • Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America.  49:1-45. 2009
  • A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.  48:1676-1684. 2009
  • A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.  48:1775-1783. 2009
  • HIV policy: The path forward- A joint position paper of the HIV medicine association of the infectious diseases society of America and the American College of physicians.  48:1335-1344. 2009
  • Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal.  48:1138-1151. 2009
  • Incomplete peripheral CD4 + cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment.  48:787-794. 2009
  • Clinical practice guidelines for the management of candidiasis: 2009 Update by the Infectious Diseases Society of America.  48:503-535. 2009
  • Missed visits and mortality among patients establishing initial outpatient HIV treatment.  48:248-256. 2009
  • Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria.  47:674-683. 2008
  • Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries.  47:487-495. 2008
  • The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America.  47:303-327. 2008
  • Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis (Clinical Infectious Diseases (2007) 45, (883-893)).  47:302. 2008
  • Clinical practice guidelines for the management of blastomycosis: 2008 Update by the infectious diseases society of America.  46:1801-1812. 2008
  • Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.  46:1813-1821. 2008
  • Lactational amenorrhea as a risk factor for group a streptococcal vaginitis.  46. 2008
  • Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV Clinic.  46:1315-1318. 2008
  • High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.  46:1111-1118. 2008
  • Seasonal and pandemic influenza: A 2007 update on challenges and solutions.  46:1024-1031. 2008
  • Reply to Eiland et al..  46:641. 2008
  • Reply to Connor.  46:476-477. 2008
  • Opt-out testing: Who can afford to take care of patients with newly diagnosed HIV infection?.  45. 2007
  • Clinical practice guidelines for the management of sporotrichosis: 2007 Update by the Infectious Diseases Society of America.  45:1255-1265. 2007
  • Clinical practice guidelines for the management of patients with histoplasmosis: 2007 Update by the Infectious Diseases Society of America.  45:807-825. 2007
  • Expanding the spectrum of pathogens in urethritis: Implications for presumptive therapy?.  45:872-874. 2007
  • Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.  45:883-893. 2007
  • The incidence and severity of herpes simplex encephalitis in Sweden, 1990-2001.  45:881-882. 2007
  • Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.  45:658-661. 2007
  • Persistence of nevirapine in breast milk after discontinuation of treatment.  45:391-394. 2007
  • Failure to establish HIV care: Characterizing the "no show" phenomenon.  45:127-130. 2007
  • Management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: Evidence reviewed for the 2006 centers for disease control and prevention sexually transmitted diseases treatment guidelines.  44. 2007
  • Management of women with cervicitis.  44. 2007
  • Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.  44:726-734. 2007
  • Reply to Behrens et al. [4].  44:762-763. 2007
  • Factors associated with seronegative chronic hepatitis C virus infection in HIV infection.  44:577-583. 2007
  • A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis.  44:213-219. 2007
  • Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients.  44:245-249. 2007
  • Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?.  44:135-138. 2007
  • Recommendations for the management of herpes zoster.  44. 2007
  • Trichomonas vaginalis infection in male sexual partners: Implications for diagnosis, treatment, and prevention.  44:13-22. 2007
  • Trichomonas vaginalis infection: The most prevalent nonviral sexually transmitted infection receives the least public health attention.  44:23-25. 2007
  • The practice of travel medicine: Guidelines by the infectious diseases society of America.  43:1499-1539. 2006
  • Which policy to ADAP-T: Waiting lists or waiting lines?.  43:1365-1367. 2006
  • Recurrent benign lymphocytic meningitis.  43:1194-1197. 2006
  • Clinical research in the lay press: Irresponsible journalism raises a huge dose of doubt.  43:1031-1039. 2006
  • Reply to Tong et al. [4].  43:542-544. 2006
  • Invasive fungal pathogens: Current epidemiological trends.  43. 2006
  • Antifungal therapy: Lessons learned over the past 27 years.  42:1289-1296. 2006
  • Distribution of health care expenditures for HIV-infected patients.  42:1003-1010. 2006
  • Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.  42:870-877. 2006
  • Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study.  42:401-407. 2006
  • Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.  42:126-131. 2006
  • Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.  41:1326-1332. 2005
  • Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons.  41:1045-1048. 2005
  • Multicenter clinical evaluation of the (1→3) β-D-glucan assay as an aid to diagnosis of fungal infections in humans.  41:654-659. 2005
  • Trends in cancer incidence rates among HIV-infected patients [3] (multiple letters).  41:124-127. 2005
  • The use of dexamethasone in bacterial meningitis [2] (multiple letters).  40:1061-1063. 2005
  • Human herpesvirus 6 infection of the central nervous system: Is it just a case of mistaken association?.  40:894-895. 2005
  • Managing cryptococcal meningitis is about handling the pressure.  40:480-482. 2005
  • Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America.  39:1307-1313. 2004
  • Practice guidelines for the management of bacterial meningitis.  39:1267-1284. 2004
  • Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.  39:1380-1384. 2004
  • Anemia in HIV infection: Clinical impact and evidence-based management strategies.  38:1454-1463. 2004
  • Antiretroviral drug content in products from developing countries.  38:1317-1319. 2004
  • Interval between births and risk of congenital cytomegalovirus infection.  38:1035-1037. 2004
  • Guidelines for Treatment of Candidiasis.  38:161-189. 2004
  • Donor-Related Coccidioidomycosis in Organ Transplant Recipients.  37:1265-1269. 2003
  • A prospective observational study of candidemia: Epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.  37:634-643. 2003
  • Duration of highly active antiretroviral therapy regimens.  37:714-722. 2003
  • Prophylaxis against dialysis catheter-related bacteremia with a novel antimicrobial lock solution.  36:1539-1544. 2003
  • A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.  36:1221-1228. 2003
  • Methods for integration of pharmacokinetic and phenotypic information in the treatment of infection with human immunodeficiency virus.  36:373-377. 2003
  • A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: Correlations with CD4 cell count and plasma HIV-1 RNA level.  36:207-211. 2003
  • Comparative analysis of commercial assays for the detection and quantification of human immunodeficiency virus type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C.  35:323-325. 2002
  • Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: A report of 12 cases.  33:1914-1921. 2001
  • The impact of culture isolation of Aspergillus species: A hospital-based survey of aspergillosis.  33:1824-1833. 2001
  • Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.  33:690-699. 2001
  • Invasive mold infections in allogeneic bone marrow transplant recipients.  32:1319-1324. 2001
  • Multicenter case-control study of risk factors for histoplasmosis in human immunodeficiency virus-infected persons.  32:1215-1220. 2001
  • Internet and computer-based resources for travel medicine practitioners.  32:757-765. 2001
  • Influence of the normal menstrual cycle on vaginal microflora [6].  32:325. 2001
  • Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32: 320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32: 321) [1].  32:518-519. 2001
  • Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.  30. 2000
  • Institutional factors associated with resistance to third generation cephalosporin's in Klebsiella pneumonia isolates from 26 U.S. hospitals [Abstract 82] 2000
  • A pilot study evaluating ceftriaxone and penicillin G as treatment agents for neurosyphilis in human immunodeficieney virus-infected individuals.  30:540-544. 2000
  • Candiduria: A randomized, double-blind study of treatment with fluconazole and placebo.  30:19-24. 2000
  • Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis.  30:47-54. 2000
  • Sporotrichosis in Peru: Description of an area of hyperendemicity.  30:65-70. 2000
  • Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998.  31:76-79. 2000
  • Practice guidelines for the management of cryptococcal disease.  30:710-718. 2000
  • Practice guidelines for the management of patients with blastomycosis.  30:679-683. 2000
  • Practice guidelines for the treatment of candidiasis.  30:662-678. 2000
  • Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.  31:1095-1097. 2000
  • Refractory mucosal candidiasis in advanced human immunodeficiency virus infection.  30:749-756. 2000
  • Screening for latent tuberculosis in sexually transmitted disease clinics [4].  30:986. 2000
  • A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis.  28:291-298. 1999
  • A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group..  28:291-296. 1999
  • Determinants of vancomycin use in adult intensive care units in 41 United States hospitals.  28:1119-1125. 1999
  • Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project ICARE phase 2.  29:245-252. 1999
  • Herpes simplex viruses.  26:541-555. 1998
  • Vertebral blastomycosis with paravertebral abscess: Report of eight cases and review of the literature.  26:413-418. 1998
  • Capsular polysaccharide types of group b streptococcal isolates from neonates wtth early-onset systemic infection.  25:439. 1997
  • Changing frequency of early-onset group B streptococcal disease(EOGBS) in neonates from 1992 to 1996.  25:409. 1997
  • Cryptococcosis in non-HIV infected patients: A multicemer survey.  25:379. 1997
  • Current trends in nosocomial candidemia: Results of a large multienter study.  25:357. 1997
  • Long term virological and immunological effect of the HIV protease inhibitor, VIRACEPT® (nelfinavir mesylate, NFV) in combination with zidovudine (AZT) and lamivudine (3TC).  25:396. 1997
  • Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  25:200-205. 1997
  • Cardiac arrhythmias associated with coadministration of azole compounds and cisapride [4] (multiple letters).  24:1285. 1997
  • Treatment of blastomycosis with higher doses of fluconazole.  25:200-205. 1997
  • Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  23:996-1001. 1996
  • Fluconazole therapy for histoplasmosis.  23:996-1001. 1996
  • Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: A meta-analysis of placebo-controlled trials.  22:341-347. 1996
  • Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.  22:46-50. 1996
  • Update on the management of onychomycosis: Highlights on the Third Annual International Summit on Cutaneous Antifungal Therapy.  23:305-313. 1996
  • Herpes zoster in patients with human immunodeficiency virus infection--an ever-expanding spectrum of disease..  21:989-990. 1995
  • Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group..  21:994-996. 1995
  • Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group..  20:267-271. 1995
  • Editorial response: Herpes zoster in patients with human immunodeficiency virus infection–an ever-expanding spectrum of disease.  21:989-990. 1995
  • Editorialresponse: Clinical and host differences between infections with the two varieties of cryptococcus neoformans.  21:35-36. 1995
  • Guidelines for the prevention and treatment of B-virus infections in exposed persons.  20:421-439. 1995
  • Herpes simplex virus infections of the central nervous system: Therapeutic and diagnostic considerations.  20:414-420. 1995
  • Herpesvirus infections in persons infected with human immunodeficiency virus.  21. 1995
  • Human herpesvirus 6 is associated with focal encephalitis.  21:571-576. 1995
  • Intravascular catheter exchange and duration of candidemia.  21:994-996. 1995
  • Pentamidine Concentrations in a Mother with AIDS and in Her Neonate.  20:1569-1570. 1995
  • Pretransplantation assessment of the risk of lymphoproliferative disorder.  20:1346-1353. 1995
  • Treatment of blastomycosis with fluconazole: A pilot study.  20:267-271. 1995
  • USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: Disease-specific recommendations.  21. 1995
  • Diagnosing neurosyphilis..  18:295-297. 1994
  • Editorial response: Diagnosing neurosyphilis.  18:295-297. 1994
  • Human immunodeficiency virus infection.  18:963-973. 1994
  • Intraocular blastomycosis: Case report and review.  18:805-807. 1994
  • Measurement of cryptococcal antigen in serum and cerebrospinal fluid: Value in the management of aids-associated cryptococcal meningitis.  18:789-792. 1994
  • Pulmonary infection due to legionella cincinnatiensis in renal transplant recipients: Two cases and implications for laboratory diagnosis.  18:385-389. 1994
  • Evaluation of new anti-infective drugs for the treatment of infection with human immunodeficiency virus.  17:794-801. 1993
  • Evaluation of new anti-infective drugs for the treatment of infection with human immunodeficiency virus. The European Working Party of the European Society of Clinical Microbiology and Infectious Diseases..  17:794-801. 1993
  • Radiographic Changes Associated with Tracheal Isolation of Ureaplasma Urealyticum from Neonates.  17:S122-S130. 1993
  • Systemic Neonatal Infection Due to Ureaplasma urealyticum.  17:S131-S135. 1993
  • Therapeutic Considerations for Ureaplasma urealyticum Infections in Neonates.  17:S208-S214. 1993
  • Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S182-S188. 1992
  • Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S189-S194. 1992
  • Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S200-S205. 1992
  • Evaluation of new anti-infective drugs for the treatment of viral encephalitis. Infectious Diseases Society of America and the Food and Drug Administration..  15 Suppl 1:S195-S199. 1992
  • Evaluation of new anti-infective drugs for the treatment of acute bacterial meningitis.  15:S182-S188. 1992
  • Evaluation of new anti-infective drugs for the treatment of cryptococcal meningitis.  15:S189-SI94. 1992
  • Evaluation of new anti-infective drugs for the treatment of toxoplasma encephalitis.  15:S200-S205. 1992
  • Evaluation of new anti-infective drugs for the treatment of viral encephalitis.  15:S195-S199. 1992
  • Geographic Distribution of Penicillin-Resistant Clones of Streptococcus pneumoniae: Characterization by Penicillin-Binding Protein Profile, Surface Protein A Typing, and Multilocus Enzyme Analysis.  15:112-118. 1992
  • The management of pregnancies complicated by genital infections with herpes simplex virus.  15:1031-1038. 1992